Catawba Research Forms Strategic Alliance with PharmaLegacy
Catawba Research, a prominent global full-service Clinical Research Organization (CRO), is excited to unveil a new strategic partnership with PharmaLegacy Laboratories, a recognized industry leader in preclinical contract research services. This collaboration aims to maximize the strengths of both companies, driving innovation and excellence in drug development. Notably, this partnership will also provide Catawba Research with expanded access to markets, enhancing its capabilities across the Asia-Pacific region.
Expertise in Preclinical Research
PharmaLegacy Laboratories is known for its advanced preclinical models and pharmacology research, focusing on supporting biotechnology and pharmaceutical companies throughout their drug discovery and development processes. This strategic partnership significantly enhances Catawba Research’s agile solutions and scientific focus, setting the stage for groundbreaking advancements in clinical trial methodologies.
A Thrilling New Venture
“We are thrilled to partner with PharmaLegacy,” expressed Andy Silverman, CEO of Catawba Research. “Their extensive experience in preclinical research aligns perfectly with our commitment to delivering high-quality, efficient clinical trial management. By working together, we can offer comprehensive solutions for our clients in drug development, ensuring a faster and more efficient process while adhering to the highest standards of scientific integrity.”
Benefits for Clients
Jeff Duan, the CEO of PharmaLegacy, shared his enthusiasm about the collaboration: “Catawba Research has an outstanding reputation in the clinical research arena, and we believe that by merging our capabilities, we can provide a holistic research experience for our clients. Our joint efforts will focus on delivering new therapies to patients more effectively.”
This partnership is designed to streamline drug development for customers. They will now have a single source for both preclinical and clinical trial services. With the combined expertise from both companies, drug candidates will be rigorously tested and validated, facilitating faster delivery of innovative treatments to patients in need.
About Catawba Research
Catawba Research is a notable global full-service Clinical Research Organization, providing oversight, management, and execution of Phase II and Phase III clinical trials. The company collaborates with drug development sponsors to advance innovative therapies to the global marketplace.
About PharmaLegacy Laboratories
PharmaLegacy Laboratories, based in Shanghai, stands as a leading preclinical Contract Research Organization. The company is dedicated to expediting the adoption of new therapies, which results from the integration of new drug R&D and translational research. PharmaLegacy is committed to delivering clinically relevant, science-based specialty pharmacology and toxicology services to pharmaceutical and biotech firms globally, enabling the successful development of new drugs and therapies.
Frequently Asked Questions
What is the goal of the partnership between Catawba Research and PharmaLegacy?
The partnership aims to combine both companies' strengths to enhance drug development processes and provide a comprehensive research experience for clients.
Who are the CEOs involved in this partnership?
Andy Silverman is the CEO of Catawba Research, and Jeff Duan is the CEO of PharmaLegacy Laboratories.
What services do Catawba Research and PharmaLegacy offer?
Catawba offers Phase II and III trial management, while PharmaLegacy specializes in preclinical research services and advanced pharmacology.
How will this partnership benefit drug development?
By streamlining the research process, the partnership allows for rigorous testing and validation of drug candidates, leading to faster delivery of new therapies.
Where is PharmaLegacy Laboratories headquartered?
PharmaLegacy Laboratories is headquartered in Shanghai, China, focusing on providing global preclinical research services.
